Protocol Ledger

NCT07230132 · Phase II · ACTIVE NOT RECRUITING

Efficacy and Safety of ZT006 in Overweight and Obese Participants

Interventional Phase II clinical trial protocol NCT07230132 sponsored by Beijing QL Biopharmaceutical Co in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-12 Enrollment: 184 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07230132
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)184 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07230132
Protocol FieldVerified Registry Value
NCT IdentifierNCT07230132
Consolidated Lead SponsorBeijing QL Biopharmaceutical Co
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment184 participants (ACTUAL)
Registered Start Date2025-12-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07230132
Hospital Research SiteLocationSite Profile
The Second Affiliated Hospital of Nanjing Medical UniversityNanjing, ChinaOpen Hospital Dossier ->
First Hospital of Shanxi Medical UniversityTaiyuan, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI